The data, however, suggest that Gleevec, generically known as imatinib, provides a treatment benefit. ❋ Unknown (2008)
Among Thomson Reuters favorites for the Medicine prize are three scientists from the United States -- Brian Druker, Nicholas Lydon and Charles Sawyers -- who discovered and developed ground-breaking new drugs called imatinib and dasatinib for the treatment of chronic myeloid leukemia CML. ❋ Unknown (2011)
Drug-chemo combo doubles survival in high-risk childhood leukaemia patients WASHINGTON - A new study has revealed that daily doses of a targeted drug called imatinib mesylate along with regular chemotherapy can almost double the survival rate of children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). ❋ Ians (2010)
Since 2002, a cancer drug known as imatinib (Gleevec) has been used against GIST tumors that have a particular mutation called KIT. ❋ Unknown (2010)
WASHINGTON - A new study has revealed that daily doses of a targeted drug called imatinib mesylate along with regular chemotherapy can almost double the survival rate of children with ❋ Unknown (2010)
Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid ❋ Unknown (2010)
Individuals with chronic myeloid leukemia (CML) are first treated with a drug known as imatinib mesylate. ❋ Unknown (2009)
Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for ❋ Unknown (2009)
Oct 7 (ANI): A new study has revealed that daily doses of a targeted drug called imatinib mesylate along with regular chemotherapy can almost double the survival rate of An estimated 4,700 Canadians will learn they have leukemia in 2009, according to the Canadian Society. ❋ Unknown (2009)
Using this knowledge, the scientists have identified a drug substance called imatinib, which can inhibit the first signal pathway without affecting the other, protective, pathway. ❋ Unknown (2009)
In a previous study by Andrey Frolov, PhD, and Andrew Godwin, PhD, at Fox Chase Cancer Center in Philadelphia, PA, the same four genes were associated with the effectiveness of treatment of GIST with imatinib, which is given as front-line drug therapy for patients who are diagnosed with metastasis or who have GIST tumors that cannot be removed surgically. ❋ Unknown (2009)
Five commonly used chemotherapy drugs doxorubicin, cisplatin, methotrexate, vincristine and Gleevec, also known as imatinib, were tested and Dr. Heaney says while the vitamin C did not neutralize the effects of the chemotherapy drugs, it blunted their effects. ❋ Unknown (2008)
The study is being conducted with patients whose disease progressed even after prior therapies such as imatinib and sunitinib.
"Our findings also suggest that maintaining the level of this microRNA might represent a new therapeutic strategy for CML blast crisis patients who do not benefit from targeted agents such as imatinib (Gleevec) and dasatinib (Sprycel)," Perrotti added. ❋ Unknown (2010)
The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. ❋ P Ljungman (2010)
